

Anti-Factor X Reference Antibody (Roche patent anti-Factor X)

Catalog # APR11296

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P00742
Reactivity	Human
Clonality	Monoclonal
Isotype	mIgG1-TW-DD
Calculated MW	54732

Additional Information

Target/Specificity	Factor X
Expression system	CHO

Protein Information


Name	F10
Function	Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting (PubMed:22409427, PubMed:39880037). Factor Xa activates pro-inflammatory signaling pathways in a protease- activated receptor (PAR)-dependent manner (PubMed:24041930, PubMed:30568593, PubMed:34831181, PubMed:18202198). Up-regulates expression of protease-activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells (PubMed:35738824). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1/F2R-dependent manner (PubMed:30568593, PubMed:34831181). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF/TNF, IL-1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Activates pro-inflammatory and pro-fibrotic responses in dermal fibroblasts and enhances wound healing probably via PAR- 2/F2RL1-dependent mechanism (PubMed:18202198). Activates barrier protective signaling responses in endothelial cells in

PAR-2/F2RL1- dependent manner; the activity depends on the cleavage of PAR-2/F2RL1 by factor Xa (PubMed:[22409427](#)). Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues (PubMed:[24041930](#)).


Cellular Location Secreted.

Tissue Location Plasma; synthesized in the liver.


Images



Anti-Factor X Reference Antibody (Roche patent anti-Factor X) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-Factor X Reference Antibody (Roche patent anti-Factor X) is 99.51%, determined by SEC-HPLC.



Immobilized Factor X-His at 8 µg/mL can bind Roche patent anti-Factor X, EC₅₀= 0.01667 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.